BridgeBio Pharma, Inc. filings document a commercial-stage biopharmaceutical company focused on medicines for genetic conditions, including financial results, product revenue disclosures, program updates, and formal reports on ATTR-CM, LGMD2I/R9, and achondroplasia development programs.
Its SEC record includes Form 8-K disclosures for results of operations, Regulation FD presentations, clinical and regulatory press releases, material agreements, an at-the-market equity distribution agreement, convertible senior notes, and a board-authorized stock repurchase program. Proxy materials address director elections, executive compensation votes, auditor ratification, incentive plan share reserves, governance structure, and stockholder voting matters.
BridgeBio Pharma, Inc. director Andrea Ellis exercised stock options and sold shares in a pre‑planned trade. On March 4, 2026, Ellis exercised options for 64,921 shares of common stock at $8.45 per share, converting a previously held stock option that had vested in three annual installments beginning on June 22, 2023 and ending on June 22, 2025. The same day, Ellis sold 64,921 shares of common stock at a weighted average price of $64.8681 per share, within a range of $64.255 to $65.21, under a Rule 10b5‑1 sales plan adopted on December 3, 2025, and held 18,589 shares directly afterward.
BridgeBio Pharma director Hannah Valantine exercised stock options for 25,484 shares on February 27, 2026, converting a “Stock Option (Right to Buy)” into common stock at an exercise price of $0.00 per share, with the resulting common shares reported at $48.45 per share.
On the same date, she sold 14,584 common shares at a weighted average price of $67.0793 and 10,900 shares at $67.8437 in open-market transactions executed under a Rule 10b5‑1 sales plan adopted on November 14, 2025. After these trades, she held 7,465 common shares directly and 398 shares indirectly through her spouse.
BridgeBio Pharma’s Chief Accounting Officer, Maricel Apuli, reported an open-market sale of 2,000 shares of common stock on February 26, 2026 at $66 per share. The transaction was executed under a pre-arranged Rule 10b5-1 sales plan adopted on September 8, 2025. Following this sale, Apuli directly holds 121,945 BridgeBio shares.
BridgeBio Pharma is a commercial-stage biopharmaceutical company focused on genetically driven diseases, built around a hub-and-spoke portfolio model. Its lead product, Attruby (acoramidis) for transthyretin amyloid cardiomyopathy, generated $362.4 million in 2025 U.S. net product revenue, supported by 7,804 unique patient prescriptions and 1,856 prescribing clinicians.
Ex‑U.S., acoramidis is marketed as Beyonttra through Bayer in Europe and Alexion in Japan, contributing license, services, and royalty revenue after 2025 approvals. The company reports multiple late‑stage wins: positive Phase 3 data for infigratinib in achondroplasia, encaleret in autosomal dominant hypocalcemia type 1, and BBP‑418 in LGMD2I/R9, with planned NDA and MAA submissions starting in 2026.
BridgeBio is also advancing encaleret for chronic hypoparathyroidism, infigratinib for hypochondroplasia, and BBP‑812 for Canavan disease, plus an ATTR-CM antibody depleter program. Key risks highlighted include reliance on Attruby/Beyonttra, pricing and reimbursement pressure, clinical and regulatory uncertainty, manufacturing dependence on third parties, and substantial ongoing capital needs.
BridgeBio Pharma reported strong 2025 revenue growth but remains deeply loss-making as it scales commercial and late‑stage programs. Total revenues, net reached $502.1 million for 2025, up from $221.9 million in 2024, driven largely by $362.4 million in Attruby net product revenue and higher royalties from BEYONTTRA.
Operating costs and expenses climbed to $1.03 billion, mainly from a $242.3 million increase in selling, general and administrative spending to support launches, partially offset by lower R&D. Net loss attributable to common stockholders widened to $724.9 million with loss per share of $3.78.
Cash, cash equivalents and marketable securities were $587.5 million at year-end. The company issued $575.0 million of 2031 notes, executed a $300.0 million royalty deal, repaid a $459.0 million term loan and repurchased $48.3 million of stock. BridgeBio highlighted three positive Phase 3 readouts (BBP-418, encaleret, infigratinib) and is planning multiple NDA submissions beginning in the first half of 2026.
BridgeBio Pharma, Inc. Chief Executive Officer Neil Kumar reported open-market sales of a total of 28,053 shares of common stock on February 19, 2026. The sales were executed in three tranches of 18,923, 8,528 and 602 shares at weighted average prices of $71.0347, $72.0804 and $72.8010 per share, respectively, pursuant to a pre-arranged Rule 10b5-1 sales plan adopted on March 31, 2025.
Following these transactions, Kumar directly owned 234,451 shares of BridgeBio common stock. He also had indirect ownership of 675,686 shares through the Kumar Haldea Family Irrevocable Trust and 4,478,447 shares through the Kumar Haldea Revocable Trust, as co-trustee, while disclaiming beneficial ownership except to the extent of any pecuniary interest.
Reporting persons including Neil Kumar and related trusts reported proposed sales of Common stock under Rule 144. The filing lists multiple 10b5-1 scheduled sales between 11/20/2025 and 02/16/2026, including examples of NEIL KUMAR 30,011 shares and KUMAR HALDEA REVOCABLE TRUST 20,000 shares. The securities are Common stock held at Morgan Stanley Smith Barney LLC.
BridgeBio Pharma, Inc. director and CEO Neil Kumar reported equity compensation-related transactions involving restricted stock units (RSUs) and common stock on February 16, 2026. He acquired multiple blocks of common stock at $0.00 per share through the exercise or conversion of RSUs, which each represent a contingent right to receive one share of common stock.
To cover tax obligations triggered by the vesting of 64,698 RSU-based shares, 30,970 shares of common stock were disposed of at $75.25 per share via share withholding, rather than an open-market sale. Following these transactions, he continued to hold a significant number of shares directly, and additional common stock is held indirectly through the Kumar Haldea Family Irrevocable Trust and the Kumar Haldea Revocable Trust, where he is a co-trustee. He disclaims beneficial ownership of the trust-held shares except to the extent of any pecuniary interest.